CAPSULaser in Cases of Intumescent Cataract

evaluating the use of selective laser in doing capsulotomy in intumescent cataract

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intumescent Cataract Cataract Eye Diseases Lens Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Magrabi eye hospitals

Jeddah, Jedda, 22233, Saudi Arabia

About this study

Evaluating the safety and advantages of using selective laser capsulotomy for capsulorhexis creation in intumescent cataract

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with intumescent cataract and good pupil dilatation

Exclusion criteria

absence of corneal scaring

Treatment and study plan

CAPSULaser

Procedure

doing capsulotomy using CAPSULaser

capsulotomy

Device

capsulorhexis using CAPSULaser

Primary outcomes

To measure the actual size compared to result size as measured by slit lamp in mm

Time frame: 3 months

To measure the actual size compared to result size as measured by slit lamp
Incidence and number of extended capsulorhexis to the total number of cases

Time frame: 1 month

Incidence and number of extended capsulorhexis

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Evaluating the Safety and Advantages of Using Selective Laser Capsulotomy to Create Capsulorhexis in Cases Intumescent Cataract

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Dec 5, 2025
Registry last updated: Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed